Kornimate/medical-research-clean huggingface dataset:
effect of intravenous ferric carboxymaltose on reverse remodeling following cardiac resynchronization therapy

Conditions: Heart Failure

Summary: to assess impact on left ventricular reverse remodeling defined as a change in left ventricular ejection fraction in heart failure patients with reduced ejection fraction (and previous implantation of cardiac resynchronization therapy) undergoing treatment with ferric carboxymaltose vs. placebo


Eligibility criteria:
inclusion criteria: 1. chronic heart failure and implantation of cardiac resynchronization therapy more than 6 months ago and presence of iron deficiency (ferritin \< 100 μg/l, irrespective of tsat or ferritine between 100 - 300 μg/l with tsat \< 20%) and presence of incomplete reverse remodeling (lvef \< 40%). 2. age ≥18 years 3. obtained informed consent 4. stable pharmacological therapy of heart failure during the last 4 weeks (with the exception of diuretics) exclusion criteria: 1. hemochromatosis, iron overload, defined as tsat \> 45% 2. hemoglobin \> 15 g/dl at inclusion 3. known hypersensitivity to injectafer®. 4. known active infection, crp\>20 mg/l, clinically significant bleeding, active malignancy. 5. chronic liver disease and/or screening alanine transaminase (alt) or aspartate transaminase (ast) above three times the upper limit of the normal range. 6. immunosuppressive therapy or renal dialysis (current or planned within the next 6 months). 7. history of erythropoietin, i. v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months. 8. unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias. 9. acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke within the last 3 months. 10. coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months. 11. inability to fully comprehend and/or perform study procedures in the investigator's opinion. 12. vitamin b12 and/or serum folate deficiency according to the laboratory (re-screening is possible after substitution therapy). 13. pregnancy or lactation. 14. participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study. 15. planned cardiac hospitalization during study follow-up
sensory rehabilitation in chemotherapy induced peripheral neuropathy (cipn)

Conditions: CIPN

Summary: physiotherapist research about sensory rehabilitation in chemotherapy induced peripheral neuropathy (cipn) with the aid of questioners and physiotherapy practice


Eligibility criteria:
inclusion criteria: * patients aged 18 and over who suffer from chemotherapy-induced neuropathy (cipn), according to the patient's report, more than 3 months since the end of the chemotherapy treatment. exclusion criteria: 1. sensory damage / neuropathy that existed even before the start of chemotherapy 2. incidents of recurrent falls even before the start of chemotherapy (over 2 falls for 6 months) 3. central nervous system involvement 4. major pre-morbid orthopedic lower limb impairment 5. hebrew language not sufficient for assessment and treatment

Keywords: neuropathic pain chemo induced peripheral neuropathy (cipn) sensory rehabilitation explicit sensory retraining
biomarkers of intestinal mucosal healing in crohn's disease (p08143)

Conditions: Crohn Disease

Summary: this study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of crohn's disease (cd) of at least 6 weeks duration, or acute diagnosis of sufficiently severe cd warranting initiation of infliximab sooner than allowed by fecal calprotectin turnaround time * history of colonic involvement verified by prior endoscopy or radiography * indicated for treatment with infliximab according to current best medical practice * body mass index (bmi) between 15 kg/m\^2 and 35 kg/m\^2 * women of childbearing potential and non-vasectomized men agree to use medically-acceptable contraception * negative pregnancy test * no signs or symptoms of active tuberculosis (tb) and has a negative tb test within 6 weeks of first study drug administration exclusion criteria: * pregnancy, intention to become pregnant, or breastfeeding * evidence of a colon unaffected by cd * indication for surgery * perianal disease likely to interfere with study participation * presence of a stoma or history of colectomy * symptomatic diarrhea unrelated to cd * strictures or evidence of bowel obstruction * presence of abscess unless completed definitive treatment can be documented one week prior to screening * presence of fistulas * contraindication to infliximab * intolerance to sedatives or other medications required for endoscopy * any prior use of anti-inflammatory biologic therapy * moderate or severe congestive heart failure * history of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis * major surgery or donation/loss of at least one unit of blood within 4 weeks of screening * positive for hepatitis b surface antigen, hepatitis c antibodies, or human immunodeficiency virus (hiv) * history of any tumor except adequately treated basal cell carcinoma or carcinoma in situ of the cervix * history of systemic granulomatous infection * history of nontuberculous mycobacterial disease, or any opportunistic infection within 12 months of study entry * transplanted organ including bone marrow or hematopoietic stem cell-derived marrow

Keywords: biological markers endoscopy gastrointestinal
promoting healing of nerves through electrical stimulation

Conditions: Cubital Tunnel Syndrome; Nerve Compression; Nerve Injury; Ulnar Neuropathies

Summary: this study is evaluating a new therapeutic use of electrical stimulation to promote nerve healing and improve functional recovery following surgical intervention for nerve compression. a single dose of the therapeutic stimulation is delivered as part of the surgical intervention to address compression of the ulnar nerve at the elbow.

preliminary research has shown that delivering a brief period of electrical stimulation following nerve repair promotes nerve healing and functional recovery. this study is investigating the use of a single dose of therapeutic electrical stimulation to promote nerve healing. the therapy is delivered as part of the surgical intervention to address compression of the ulnar nerve at the elbow, commonly referred to as cubital tunnel syndrome.

Eligibility criteria:
inclusion criteria: * electrodiagnostic evidence of ulnar neuropathy at the elbow. * are candidates for surgical intervention. * evidence of motor involvement such as intrinsic muscle atrophy or weakness. * are age 18-80 years. * signed and dated informed consent form. exclusion criteria: * severe comorbid condition, such as arrythmia or congestive heart failure, preventing surgery * previous history or current transection of ulnar nerve, or concomitant upper extremity nerve injury * global peripheral neuropathy affecting the hands * age less than 18 or greater than 80 years * un-affected hand maximum grip strength \<12kg

Keywords: therapeutic electrical stimulation nerve regeneration nerve healing nerve injury cubital tunnel ulnar nerve
analysis of spread level during thoracic erector spinae block

Conditions: Pain; Radiculopathy, Cervical

Summary: the primary purpose of this study was to identify the espb spread level in the craniocaudal direction when performed at the t2 level. the secondary purpose was to determine the incidence of spread into epidural, paravertebral, intercostal, and intravascular injections with espb

the espb requires ultrasound guidance which enables visible local anesthetic spread underneath the erector spinae muscles. the spinalis, longissimus thoracis, and iliocostalis muscles comprise the es muscles, which run vertically along both sides of the vertebral column from the sacrum up to the skull base. the espb can be performed in the cervical, thoracic, and lumbar regions. among them, upper or mid thoracic espb has been used more widely compared to cervical and lumbar regions. previous cadaveric studies on the espb at the t5 level using computed tomography (ct) reconstruction or direct dissection demonstrated the extensive craniocaudal distribution of methylene blue ranging from t1 to t8 vertebral segments deep to the es muscles and variable involvement of epidural, paravertebral, and intercostal spaces. the espb performed at the t2 level of the cadaver demonstrated an injected dye distribution ranging from c4 to t10. also, 36% of cadavers showed the spread of an injected dye to the ventral, dorsal ramus, paravertebral space, and even the contralateral side. the exact mechanism of action of espb remains unclear. a recent study suggested that the analgesic effect of espb could be obtained by blocking the ventral and dorsal ramus of the spinal nerves by passing through the costotransverse foramen. however, in clinical practice, we can encounter highly variable clinical outcomes or sensory block after the espb. the study of the physical spread of the injected agent can be used to predict the clinical result and elucidate the possible mechanism of action of espb.

Eligibility criteria:
inclusion criteria: * cervical facet joint arthrosis * cervical foraminal stenosis * cervical herniated intervertebral disc * myofascial pain syndrome of upper back muscle exclusion criteria: * allergy to local anesthetics or contrast medium * pregnancy * prior history of cervical spine surgery * coagulation abnormality
effect of cola on urinary stone risk factors

Conditions: Kidney Stone

Summary: examine the effects of cola on risks of kidney stones

prospective crossover study examining the risks of cola on stone risk factors.

Eligibility criteria:
inclusion criteria: * urolithiasis, healthy volunteer exclusion criteria: -

Keywords: urolithiasis, cola
usage of 5-fluorouracil and carnoy's solution in surgical treatment of odontogenic keratocysts

Conditions: Odontogenic Keratocyst

Summary: the goal of this clinical trial is to compare surgical treatment outcomes of odontogenic keratocysts (okc) treated with enucleation and local application of carnoy's solution or 5% 5-fluorouracil. the main questions it aims to answer are: 1. what is the recurrence rate of okc treated with enucleation and local application of 5% 5-fluorouracil cream in the period of three and five years after the treatment 2. what is the recurrence rate of okc treated with enucleation and local application of carnoy's solution in the period of three and five years after the treatment 3. is there a difference in the recurrence rate between these two groups 4. what is the frequency of sensitivity disorders in the innervation zone of inferior alveolar and infraorbital nerves in both groups participants will be assigned to one of two groups after histopathological verification (hp verification).they will be treated with enucleation and local application of carnoy's solution or 5% 5-fluorouracil depending on group. after surgical treatment they will be monitored in accordance to standard treatment protocols for patients with okc.


Eligibility criteria:
inclusion criteria: * histologically verified okc of the upper or lower jaw; * indicated surgical treatment of okc exclusion criteria: * hypersensitivity to 5-fluorouracil and carnoy's solution; * pathological fracture of the jaw in okc region. * nevoid basal cell carcinoma
sedation in the intensive care unit

Conditions: Critical Illness; Respiratory Failure

Summary: high-risk critically ill patients often require mechanical ventilation either to primarily support the respiratory function or when the ventilation is insufficient to maintain adequate gas exchanges as a result of other organ impairment. in order to tolerate this aggressive mechanical support, enhance patient synchrony with the ventilator, and relieve pain and anxiety, analgesia and sedation are provided. it is suggested that an inappropriate use of sedation and analgesia may prolong the duration of mechanical ventilation and increase the risk of specific adverse outcomes such as ventilator associated pneumonia. despite the widespread use of sedation, little information is available concerning the effect of varying the level of sedation on patients' subsequent mental health. we designed a randomized controlled trial to investigate the efficacy of sedation with the goal of maintaining the patient cooperative and interactive compared to the administration of sedation with the goal of maintaining the patient sedated. the first goal will be achieved by a discontinuous injection of a sedative, while the second goal will be achieved by a continuous infusion of the same sedative. in both groups pain relief will be provided in the same fashion with equal endpoints on a pain scoring scale. our primary aim is to investigate whether differences in the occurrence of post-traumatic stress disorders (ptsd), anxiety, and depression are related to the choice of sedation-analgesia strategies. secondary endpoints include the length of icu stay, as indicated by the time to discharge from the icu, the time to separation from mechanical ventilation, the rates of pulmonary and extra-pulmonary complications, and hospital length of stay. these endpoints will be compared between the two groups.


Eligibility criteria:
inclusion criteria: * critically ill patients requiring mechanical ventilation exclusion criteria: * neurological conditions or neuromuscular disease * chronic renal failure, liver failure * allergy to benzodiazepines or morphine * drug overdose * pregnancy * non-cooperative * treatment with hiv protease inhibitors or erythromycin * refusal of consent

Keywords: sedation, mechanical ventilation
effects of tea catechin consumption on the prophylaxis of influenza infection

Conditions: Influenza Infection

Summary: the purpose of this study is to evaluate the effects of 5 months catechin consumption on the prevention of influenza infection.

catechins are the major components of tea flavonoids and are reported to possess physiological activities such as antiviral effects. recent experimental studies have revealed that tea catechin extracts prevent influenza infection, but few studies have been conducted on the clinical effects of tea catechin consumption on the prophylaxis of influenza infection. based on these backgrounds, we designed a prospective randomized controlled study to evaluate the effects of 5 months tea catechin consumption on the prophylaxis of influenza infection.

Eligibility criteria:
inclusion criteria: * aged over 20 years * possible to maintain without drinking tea more than 250 ml per day during the study * possible to maintain without taking supplements or herbal products including catechin extracts during the study * possible to fill out a questionnaire personally * obtained written informed consent before participation exclusion criteria: * possessing some chronic infectious diseases in need of therapy * possessing tea or catechin allergy * possessing a history of influenza infection before six months prior to the study * diagnosed as inadequate for other reasons to participate the study by principal investigator

Keywords: tea catechin extracts influenza infection prophylaxis supplements adults over 20 years old both men and women
donation network to optimize organ recovery study

Conditions: Brain Death; Organ Donation

Summary: this study consists in an cluster-randomized clinical trial involving near 60 brazilian intensive care units (icus) with a high notification rate of potential donors of organs and tissues. icus will be randomized in a 1:1 ratio to manage potential organ donors through the use of a evidence-based checklist or to manage potential organ donors according usual care. the primary outcome is the rate of losses of potential donors due to cardiac arrest. secondary outcome measures include number of effective organ donors and number of organs recovery per effective donor. the first subject was enrolled on june 20, 2018.


Eligibility criteria:
inclusion criteria: for icus: * adults icus reporting at least 10 potential valid donors (without clinical contraindications for donation) per year for potential donor: * age of 14 years or older * suspected brain death after the first clinical test exclusion criteria: for icus: * coronary units, intermediate units, emergency services * icus that use checklist for the management of the potential donors for potential donors: * age \>90 years * hiv * metastatic cancer * uncontrolled sepsis * acute hepatitis * malaria * acute viral infections * cryptococcal meningoencephalitis and prion diseases * active tuberculosis treated less than 2 months * colonization of the donor by bacteria without any option of antibiotic treatment * history of breast tumor, melanoma, soft tissue sarcoma or hematologic neoplasia, who group 3 primary tumors

Keywords: intensive care units brain death organ donation family interview
use of fish oil to reduce inflammation during endovascular abdominal aortic repair

Conditions: PAD; Abdominal Aortic Aneurysm

Summary: the purpose of this study is to determine if high-dose pufa supplementation in patients undergoing evar for infra-renal aaa reduces the peri-operative inflammation.

in this 2:1 double-blind, randomized, placebo controlled trial, subjects will be given an active drug of n-3 polyunsaturated fatty acids (pufas) or a placebo soybean oil for about two weeks prior to an endovascular abdominal aortic repair (evar) and subsequently six months after the procedure. an evar is known to produce a systemic inflammatory response with an increased risk of prolonged hospitalization and complicated post-operative recovery with cardiac events, renal and pulmonary dysfunction, and multiple organ failure. the study proposed here has the potential to provide valuable insight on the role of nutritional intervention to improve outcomes related to surgical revascularization.

Eligibility criteria:
inclusion criteria: * undergoing evar for infra-renal aaa and/or iliac artery aneurysm exclusion criteria: * age \ 90 years * on dual antiplatelet therapy or anticoagulation * evidence of active infection * diagnosed hypercoagulable state * non-atherosclerotic/aneurysmal disease as indication for procedure * chronic liver disease or myopathy * end-stage renal disease (ckd 5) * poorly controlled diabetes (hba1c \> 8%) * recent other major surgery or illness within 6 weeks * use of immunosuppressive medication or extant chronic inflammatory disorders * history of organ transplantation * pregnancy or plans to become pregnant * condition in which patient life expectancy is less than one year * known allergy to fish or fish products * presence of symptomatic or ruptured aaa
a pilot study to assess the effect of intermittent ino on the treatment of ntm lung infection in cf and non-cf patients

Conditions: Non-Tuberculous Mycobacterial Pneumonia; Cystic Fibrosis; Mycobacterial Pneumonia; Mycobacterium Abscessus Infection; Mycobacterium Avium Complex

Summary: the purpose of this open-label, multicenter, non-randomized, pilot study is to assess the safety of high dose intermittent ino for treatment of ntm infection in cf and non-cf patients.

the study will include 20 patients from up to four clinical sites in australia. the overall treatment plan includes 2 weeks of inhalation treatments (intensive phase) of ino four times per day at 4.5-hour intervals followed by 10 weeks of inhalation treatments (maintenance phase) at the maximum tolerated dose (a maximum of 250 ppm no) inhaled twice daily.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with refractory ntm (mac or mabs) pulmonary infection * cf and non-cf patients exclusion criteria: * diagnosis of methemoglobinemia or methb ≥2% at screening; treatment with any drug known to increase methb; known or suspected hemoglobinopathy. * history of or current myeloproliferative disease, leukemia or other hematological malignancy; known or suspected immunodeficiency disease. * subjects with advanced cardiovascular disease or chf * use of an investigational drug during the 30 days prior to enrollment. * history of frequent epistaxis (\>1 episode/month); significant hemoptysis (during the 30 days prior to enrollment. * subject on non-constant dose of systemic steroids within 30 days prior to enrollment; subjects on constant systemic steroids if the daily dose is higher than 10 mg/d prednisolone or equivalent. * active pulmonary malignancy (primary or metastatic) or any malignancy; history of lung transplantation. * pulmonary tuberculosis requiring treatment or treated within 2 years prior to screening. * uncontrolled hypertension within 3 months prior to or at screening * diagnosis of significant pulmonary hypertension indicated on echocardiogram at screening * clinically significant renal or liver laboratory abnormalities * history of daily, continuous oxygen supplementation. * women of childbearing potential - pregnant or breastfeeding, or not on medically acceptable double methods of contraception from enrollment until day 84. * smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study. * patient receiving drugs that have a contraindication with no
vacuum myofascial therapy device in treatment of muscle fibrosis

Conditions: Muscle Injury

Summary: we present the case of a 24-year-old professional soccer player, with no personal history of interest, who came to the x-ray diagnosis service due to severe pain in the right quadriceps muscle after a 10-month evolution of muscle rupture occurred during sports practice.

physium system® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms, both in the entire muscle and in muscle fibrosis. seven days later, after physium system® session with the same parameters of the previous treatment, ultrasound elastography was performed.

Eligibility criteria:
inclusion criteria. * 24-year-old professional soccer player. * no personal medical history of interest

Keywords: negative pressure cupping physical therapy modalities